POLITICS: Sotomayor’s Headache: The United Kingdom Upholds Ban on Puberty-Blocking Drugs for Minors

In the aftermath of the contentious Supreme Court arguments in United States v. Skrmetti over state bans on puberty blockers and gender-altering surgeries, the United Kingdom reaffirmed that it finds the risks far outweigh the benefits of such treatments for minors under the currently available scientific evidence. The move by the liberal Labour Party stands in sharp contrast with the portrayal of the Biden Administration and the treatment of the subject by the liberal justices. Justice Sonia Sotomayor was widely criticized for analogizing puberty-blocking drugs to taking aspirin. It appears that doctors in the UK are not ready to tell minors to just “take two puberty-blocking drugs and call me in the morning.”

UK Health Secretary Wes Streeting said last week, “Children’s health care must always be evidence-led. The independent expert Commission on Human Medicines found that the current prescribing and care pathway for gender dysphoria and incongruence presents an unacceptable safety risk for children and young people.”

The decision follows the release of the Cass Review, which was raised by the conservative justices as contradicting the factual representations of the Biden Administration, even leading Justice Samuel Alito to suggest that Solicitor General Elizabeth Prelogar and the government might not have fulfilled their duty of candor to the tribunal. He noted that the Cass study found scant evidence that the benefits of transgender treatment are greater than the risks. He then delivered the haymaker: “I wonder if you would like to stand by the statement in your position or if you think it would now be appropriate to modify that and withdraw your statement.”

Streeting cited significant doubts about the benefits of puberty blockers while noting the “significant risks” to children.

The government will allow puberty blockers to be administered to children in clinical trials.

It is not clear if the Supreme Court will take “judicial notice” of the new decision, but it can.

This is clearly more than the risks associated with aspirin and Streeting echoed what the states argued to the Supreme Court that the government must “act with caution and care when it comes to this vulnerable group of young people, and follow the expert advice.”

POLITICS: Migrants Turning Back as Trump Border Policies Loom – The Beltway Report